A groundbreaking study from Virginia Tech's Fralin Biomedical Research Institute is challenging a decades-old assumption about how the brain's movement center works — with profound implications for understanding and treating chronic neurological conditions such as dystonia, ataxia, and tremor.
For years, neuroscientists have focused on the relationship between two types of brain cells in the cerebellum. Purkinje cells suppress activity in deep cerebellar nuclei cells, and researchers have generally assumed that observing Purkinje cell activity provides a reliable picture of what is happening in the deep nuclei cells.
New research led by Dr. Meike van der Heijden suggests that assumption may not hold true.
A Questionable Assumption
Published in The Journal of Physiology, the study found that activity in one cell type does not reliably predict activity in the other, despite their direct anatomical connection.
"We see that there's not a clear linear relationship between activity in the Purkinje cells and in the deep nuclei cells," said Van der Heijden, assistant professor at the institute. "So there's very limited predictive power in monitoring one to understand what's going on in the other."
The findings are particularly significant because Purkinje cells have received the most attention from researchers — they sit in the outer layer of the cerebellum, making them much easier to study than deep nuclei cells, which are buried deeper beneath the brain's surface.
Implications for Treatment
The discovery suggests many studies may have been relying on the wrong signals when investigating movement disorders. "We suggest that if you want to know how the cerebellum is behaving in a disease state, you have to look at the deep nuclei neurons, not just the Purkinje cells," Van der Heijden said.
This could reshape how scientists approach treatments that focus on altering Purkinje cell activity with the expectation that deep nuclei cells will respond accordingly. "This is a cautionary tale for understanding cerebellar activity in disease, but also for treating these challenging diseases," Van der Heijden added.
